Changes in the plasma membrane in metabolic disease

impact of the membrane environment on G protein-coupled receptor structure and function

Aditya J. Desai, Laurence J Miller

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Drug development targeting GPCRs often utilizes model heterologous cell expression systems, reflecting an implicit assumption that the membrane environment has little functional impact on these receptors or on their responsiveness to drugs. However, much recent data have illustrated that membrane components can have an important functional impact on intrinsic membrane proteins. This review is directed toward gaining a better understanding of the structure of the plasma membrane in health and disease, and how this organelle can influence GPCR structure, function and regulation. It is important to recognize that the membrane provides a potential mode of lateral allosteric regulation of GPCRs and can affect the effectiveness of drugs and their biological responses in various disease states, which can even vary among individuals across the population. The type 1 cholecystokinin receptor is reviewed as an exemplar of a class A GPCR that is affected in this way by changes in the plasma membrane. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.

Original languageEnglish (US)
Pages (from-to)4009-4025
Number of pages17
JournalBritish Journal of Pharmacology
Volume175
Issue number21
DOIs
StatePublished - Nov 1 2018

Fingerprint

Metabolic Diseases
G-Protein-Coupled Receptors
Cell Membrane
Membranes
Allosteric Regulation
Cholecystokinin Receptors
Drug Delivery Systems
Pharmaceutical Preparations
Organelles
Membrane Proteins
Pharmacology
Health
Population

ASJC Scopus subject areas

  • Pharmacology

Cite this

Changes in the plasma membrane in metabolic disease : impact of the membrane environment on G protein-coupled receptor structure and function. / Desai, Aditya J.; Miller, Laurence J.

In: British Journal of Pharmacology, Vol. 175, No. 21, 01.11.2018, p. 4009-4025.

Research output: Contribution to journalReview article

@article{48a8c3de62d640549e1bab5adb658751,
title = "Changes in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function",
abstract = "Drug development targeting GPCRs often utilizes model heterologous cell expression systems, reflecting an implicit assumption that the membrane environment has little functional impact on these receptors or on their responsiveness to drugs. However, much recent data have illustrated that membrane components can have an important functional impact on intrinsic membrane proteins. This review is directed toward gaining a better understanding of the structure of the plasma membrane in health and disease, and how this organelle can influence GPCR structure, function and regulation. It is important to recognize that the membrane provides a potential mode of lateral allosteric regulation of GPCRs and can affect the effectiveness of drugs and their biological responses in various disease states, which can even vary among individuals across the population. The type 1 cholecystokinin receptor is reviewed as an exemplar of a class A GPCR that is affected in this way by changes in the plasma membrane. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.",
author = "Desai, {Aditya J.} and Miller, {Laurence J}",
year = "2018",
month = "11",
day = "1",
doi = "10.1111/bph.13943",
language = "English (US)",
volume = "175",
pages = "4009--4025",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "21",

}

TY - JOUR

T1 - Changes in the plasma membrane in metabolic disease

T2 - impact of the membrane environment on G protein-coupled receptor structure and function

AU - Desai, Aditya J.

AU - Miller, Laurence J

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Drug development targeting GPCRs often utilizes model heterologous cell expression systems, reflecting an implicit assumption that the membrane environment has little functional impact on these receptors or on their responsiveness to drugs. However, much recent data have illustrated that membrane components can have an important functional impact on intrinsic membrane proteins. This review is directed toward gaining a better understanding of the structure of the plasma membrane in health and disease, and how this organelle can influence GPCR structure, function and regulation. It is important to recognize that the membrane provides a potential mode of lateral allosteric regulation of GPCRs and can affect the effectiveness of drugs and their biological responses in various disease states, which can even vary among individuals across the population. The type 1 cholecystokinin receptor is reviewed as an exemplar of a class A GPCR that is affected in this way by changes in the plasma membrane. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.

AB - Drug development targeting GPCRs often utilizes model heterologous cell expression systems, reflecting an implicit assumption that the membrane environment has little functional impact on these receptors or on their responsiveness to drugs. However, much recent data have illustrated that membrane components can have an important functional impact on intrinsic membrane proteins. This review is directed toward gaining a better understanding of the structure of the plasma membrane in health and disease, and how this organelle can influence GPCR structure, function and regulation. It is important to recognize that the membrane provides a potential mode of lateral allosteric regulation of GPCRs and can affect the effectiveness of drugs and their biological responses in various disease states, which can even vary among individuals across the population. The type 1 cholecystokinin receptor is reviewed as an exemplar of a class A GPCR that is affected in this way by changes in the plasma membrane. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.

UR - http://www.scopus.com/inward/record.url?scp=85052498836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052498836&partnerID=8YFLogxK

U2 - 10.1111/bph.13943

DO - 10.1111/bph.13943

M3 - Review article

VL - 175

SP - 4009

EP - 4025

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 21

ER -